Biotechnology

Kezar Life Sciences

Kezar Life Sciences released FY2026 Q1 earnings on May 11 (EST), actual revenue USD 0, actual EPS USD -0.7837

Kezar Life Sciences released FY2025 Q4 earnings on March 27 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.9851 (forecast USD -1.3066)

Kezar Life Sciences released FY2025 annual earnings on March 27, 2026 (EST), with actual revenue USD 0 (forecast USD 0) and actual EPS USD -7.658 (forecast USD -6.77)

Kezar Life Sciences Announces FDA Approval of C-type Meeting to Discuss Zetomipzomib

Kezar Life Sciences released FY2025 Q3 earnings on November 12, 2025 (EST), with actual revenue of USD 0 (forecast USD 0) and actual EPS of USD -1.533 (forecast USD -1.9475)

Kezar Life Sciences released FY2025 9 Months earnings on November 12, 2025 (EST), actual revenue USD 0, actual EPS USD -5.6737

Kezar Life Sciences Announces Positive Results from Phase 2 Clinical Trials of Zetomipzomib

Phipps covers healthcare sector and focuses on related stocks

Kezar Life Sciences released FY2025 Q2 earnings on August 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.8744 (forecast USD -2.2866)

Kezar Life Sciences released FY2025 Semi-Annual earnings on August 13 (EST) with actual revenue of USD 0 and EPS of USD -4.1404

Kezar Life Sciences Announces FDA Lifts Clinical Hold on PORTOLA 2a Trial

Kezar Life Sciences released FY2025 Q1 earnings on May 13 (EST), actual EPS -2.2661 USD (forecast -2.5983 USD)

Kezar Life Sciences Reports Q1 2025 Financials and Positive Trial Data

Kezar Life Sciences Inc reports expected quarterly loss of $2.6 per share

Kezar Life Sciences released FY2024 Q4 earnings on March 25 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -2.7695 USD (forecast -2.72 USD)

Kezar Life Sciences released FY2024 Annual Earnings on March 25 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -11.486 USD (forecast -5.766 USD)

Kezar Life Sciences Inc Expected to Report EPS Loss of $2.88, Analysts Rating as Buy

Kezar Life Sciences released FY2024 9 Months Earnings on November 12, 2024 (EST) with actual revenue of 0 and EPS of -8.7169

Kezar Life Sciences released FY2024 Q3 earnings on November 12 (EST), actual revenue 0 (forecast 666.67 K), actual EPS -2.784 (forecast -3.15)

Kezar Life Sciences terminates mid-stage trial of experimental drug for lupus nephritis

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

SBIO

LABU

Kezar Life Sciences (KZR) has disclosed a new risk in its Regulation category, directing investors to Part I of its filings for a comprehensive discussion of potential risks. This reliance on cross-references may obscure the full risk picture for stakeholders. The average stock price target for KZR is $7.20, indicating a downside potential of -1.23%.

Tip Ranks

ALPS Medical Breakthrough

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

Kezar Life Sciences’ Risk Disclosures Rely on Cross-References, Potentially Obscuring Full Risk Picture for Investors

AUPH

Aurinia Pharmaceuticals has completed the acquisition of approximately 80.24% of Kezar Life Sciences' outstanding common stock for $6.955 per share, following a merger agreement signed on March 30, 2026. The remaining shares were converted in a follow-on merger, making Kezar a wholly owned subsidiary. The latest analyst rating for Aurinia (AUPH) is a Hold with a $15.00 price target, while Spark's AI Analyst rates it as Outperform due to strong financial performance and growth outlook, despite some risks.

Aurinia Pharma

Proshares Ultra Nasdaq Biotech

iShares US Pharma

Aurinia Pharmaceuticals Completes Acquisition of Kezar Life Sciences

Kezar Life Sciences has appointed Kevin Tang as the new Chief Executive Officer and sole director following the resignation of multiple directors and officers due to a merger. The resignations were not due to disagreements, and the individuals involved entered into separation agreements. Tang, who previously served as the sole director of the merger subsidiary, will lead the surviving corporation.

TradingView

Kevin Tang named CEO of Kezar Life Sciences as multiple directors and officers resign

ARKG

Kezar Life Sciences announced on May 11, 2026, that it has completed its merger and requested the suspension of trading on Nasdaq. The company plans to file a Form 25 to delist and deregister its shares, as well as a Form 15 to terminate registration and suspend reporting obligations under relevant sections of the SEC.

VG Health

Ark Genomic Revolution ETF

Health Care Select Sector SPDR

iShares Global Healthcare

Nasdaq

Kezar Life Sciences Announced Transfer or Voluntary Withdrawal of Listing

Kezar Life Sciences, Inc. (NASDAQ:KZR) has received a consensus rating of "Reduce" from six analysts, with two recommending a sell and four a hold. The average one-year price target is $6.00. The stock opened at $7.39, with a market cap of $54.46 million. The company reported a quarterly EPS of ($1.99), missing estimates. Institutional investors hold 67.90% of the stock. Kezar focuses on developing therapies for autoimmune diseases, with its lead candidate KZR-616 in clinical trials.

Market Beat

Kezar Life Sciences, Inc. (NASDAQ:KZR) Given Consensus Recommendation of "Reduce" by Analysts

CRBG

AKRO

ULYX

Halper Sadeh LLC is investigating Kezar Life Sciences, Equitable Holdings, and Urgent.ly for potential violations of federal securities laws and breaches of fiduciary duties. The firm is concerned that insiders may benefit financially at the expense of ordinary shareholders. They are encouraging shareholders to discuss their rights and options regarding the proposed transactions, which include KZR's sale to Aurinia Pharmaceuticals, EQH's merger with Corebridge Financial, and ULYX's sale to Agero. Halper Sadeh LLC offers legal assistance on a contingent fee basis.

prnewswire

Urgently

Equitable

Corebridge Financial

Akero Therapeutics

Urgent.ly Inc.

16:13 ETAre KZR, EQH, ULYX Obtaining Fair Deals for their Shareholders?

CNTA

Halper Sadeh LLC is investigating Apellis Pharmaceuticals (APLS), Centessa Pharmaceuticals (CNTA), and Kezar Life Sciences (KZR) for potential violations of federal securities laws and breaches of fiduciary duties. The firm is concerned that insiders may benefit financially at the expense of ordinary shareholders due to proposed transaction terms. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost. The investigations focus on the sales of these companies to larger firms, with potential for increased consideration or disclosures sought on behalf of shareholders.

Centessa Pharmaceuticals

Invesco Nasdaq Biotechnology ETF

Apellis Pharma

13:34 ETAre APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders?

Class Action Attorney Juan Monteverde is investigating mergers involving Kezar Life Sciences (KZR), Centessa Pharmaceuticals (CNTA), Affinity Bancshares (AFBI), and Apellis Pharmaceuticals (APLS). Shareholders of KZR are expected to receive $6.955 per share, CNTA $38.00 per share, AFBI $23.00 per share, and APLS $41.00 per share, along with contingent value rights in some cases. The firm has a successful track record in recovering funds for shareholders and offers free consultations for those concerned about these transactions.

Affinity Bancshares

14:15 ETSHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--KZR, CNTA, AFBI, and APLS

Kezar Life Sciences(KZR.US)